Bruno Strigini is an accomplished executive with an extensive background in the pharmaceutical industry. He has served as CEO of Novartis Oncology and president of Europe/Canada at Merck & Co, overseeing thousands of professionals in the field. His experience also includes senior positions at UCB Celltech, Schering-Plough, and SmithKline Beecham, among others. Bruno is now an active investor, advisor, and board member in a number of companies in Europe and the Americas, providing his expertise and leadership to enhance their growth and development. He is Chairman of the board of Owkin, a leading AI and machine learning company specializing in Healthcare, Partner at OneHealth Partners, a boutique firm specializing in fundraising/corporate finance/investment banking, and the founder of ARVIC AG, a Healthcare consulting and investment company based in Basel, Switzerland. With a Master of Business Administration from IMD Lausanne, a PharmD from the University of Montpellier, and a Master's degree in microbiology from Heriot-Watt University, Bruno has a broad academic background that complements his extensive practical experience, making him one of the most respected professionals in the field. He is also an elected member of the French academy of Pharmacy, and in 2014, he was awarded an honorary doctorate from UIMP in Spain.